Literature DB >> 21199899

A unique role of the cholera toxin A1-DD adjuvant for long-term plasma and memory B cell development.

Mats Bemark1, Peter Bergqvist, Anneli Stensson, Anna Holmberg, Johan Mattsson, Nils Y Lycke.   

Abstract

Adjuvants have traditionally been appreciated for their immunoenhancing effects, whereas their impact on immunological memory has largely been neglected. In this paper, we have compared three mechanistically distinct adjuvants: aluminum salts (Alum), Ribi (monophosphoryl lipid A), and the cholera toxin A1 fusion protein CTA1-DD. Their influence on long-term memory development was dramatically different. Whereas a single immunization i.p. with 4-hydroxy-3-nitrophenyl acetyl (NP)-chicken γ-globulin and adjuvant stimulated serum anti-NP IgG titers that were comparable at 5 wk, CTA1-DD-adjuvanted responses were maintained for >16 mo with a half-life of anti-NP IgG ∼36 wk, but <15 wk after Ribi or Alum. A CTA1-DD dose-dependent increase in germinal center (GC) size and numbers was found, with >60% of splenic B cell follicles hosting GC at an optimal CTA1-DD dose. Roughly 7% of these GC were NP specific. This GC-promoting effect correlated well with the persistence of long-term plasma cells in the bone marrow and memory B cells in the spleen. CTA1-DD also facilitated increased somatic hypermutation and affinity maturation of NP-specific IgG Abs in a dose-dependent fashion, hence arguing that large GC not only promotes higher Ab titers but also high-quality Ab production. Adoptive transfer of splenic CD80(+), but not CD80(-), B cells, at 1 y after immunization demonstrated functional long-term anti-NP IgG and IgM memory cells. To our knowledge, this is the first report to specifically compare and document that adjuvants can differ considerably in their support of long-term immune responses. Differential effects on the GC reaction appear to be the basis for these differences.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21199899     DOI: 10.4049/jimmunol.1002881

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  22 in total

1.  Long-lived plasma cells are generated in mucosal immune responses and contribute to the bone marrow plasma cell pool in mice.

Authors:  A Lemke; M Kraft; K Roth; R Riedel; D Lammerding; A E Hauser
Journal:  Mucosal Immunol       Date:  2015-05-06       Impact factor: 7.313

Review 2.  The regulation of gut mucosal IgA B-cell responses: recent developments.

Authors:  N Y Lycke; M Bemark
Journal:  Mucosal Immunol       Date:  2017-07-26       Impact factor: 7.313

3.  CD73 expression identifies a subset of IgM+ antigen-experienced cells with memory attributes that is T cell and CD40 signalling dependent.

Authors:  Lucas D'Souza; Sneh Lata Gupta; Vineeta Bal; Satyajit Rath; Anna George
Journal:  Immunology       Date:  2017-08-23       Impact factor: 7.397

4.  M2e-tetramer-specific memory CD4 T cells are broadly protective against influenza infection.

Authors:  D G Eliasson; A Omokanye; K Schön; U A Wenzel; V Bernasconi; M Bemark; A Kolpe; K El Bakkouri; T Ysenbaert; L Deng; W Fiers; X Saelens; N Lycke
Journal:  Mucosal Immunol       Date:  2017-03-01       Impact factor: 7.313

Review 5.  Basics of memory B-cell responses: lessons from and for the real world.

Authors:  Rachel Wong; Deepta Bhattacharya
Journal:  Immunology       Date:  2018-11-29       Impact factor: 7.397

Review 6.  Recent progress in mucosal vaccine development: potential and limitations.

Authors:  Nils Lycke
Journal:  Nat Rev Immunol       Date:  2012-07-25       Impact factor: 53.106

7.  Long-term immunogenicity of an inactivated split-virion 2009 pandemic influenza A H1N1 virus vaccine with or without aluminum adjuvant in mice.

Authors:  Wenting Xu; Mei Zheng; Feng Zhou; Ze Chen
Journal:  Clin Vaccine Immunol       Date:  2015-01-14

Review 8.  Translational Mini-Review Series on B cell subsets in disease. Reconstitution after haematopoietic stem cell transplantation - revelation of B cell developmental pathways and lineage phenotypes.

Authors:  M Bemark; J Holmqvist; J Abrahamsson; K Mellgren
Journal:  Clin Exp Immunol       Date:  2012-01       Impact factor: 4.330

Review 9.  Strategies to guide the antibody affinity maturation process.

Authors:  Nicole A Doria-Rose; M Gordon Joyce
Journal:  Curr Opin Virol       Date:  2015-04-24       Impact factor: 7.090

10.  A novel hepatitis B vaccine containing Advax™, a polysaccharide adjuvant derived from delta inulin, induces robust humoral and cellular immunity with minimal reactogenicity in preclinical testing.

Authors:  Fadi Saade; Yoshikazu Honda-Okubo; Samay Trec; Nikolai Petrovsky
Journal:  Vaccine       Date:  2013-01-07       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.